US2877253A - Therapeutic iron complex - Google Patents
Therapeutic iron complex Download PDFInfo
- Publication number
- US2877253A US2877253A US557838A US55783856A US2877253A US 2877253 A US2877253 A US 2877253A US 557838 A US557838 A US 557838A US 55783856 A US55783856 A US 55783856A US 2877253 A US2877253 A US 2877253A
- Authority
- US
- United States
- Prior art keywords
- iron
- complex
- ferrous
- glycine
- iron complex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000001225 therapeutic effect Effects 0.000 title description 3
- 150000004698 iron complex Chemical class 0.000 title description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 32
- 229910052742 iron Inorganic materials 0.000 description 14
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 10
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 8
- YJYOLOWXCPIBSY-UHFFFAOYSA-L 2-aminoacetic acid;iron(2+);sulfate Chemical compound [H+].[H+].[Fe+2].NCC([O-])=O.NCC([O-])=O.[O-]S([O-])(=O)=O YJYOLOWXCPIBSY-UHFFFAOYSA-L 0.000 description 6
- 235000003891 ferrous sulphate Nutrition 0.000 description 6
- 239000011790 ferrous sulphate Substances 0.000 description 6
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 239000004471 Glycine Substances 0.000 description 5
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 4
- 229910001448 ferrous ion Inorganic materials 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 229940082629 iron antianemic preparations Drugs 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical class OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- -1 ferrous compound Chemical class 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 150000002505 iron Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229940099990 ogen Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/295—Iron group metal compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/02—Iron compounds
- C07F15/025—Iron compounds without a metal-carbon linkage
Definitions
- the present invention relates to a therapeutic complex in which the ferrous ion is made readily available for absorption.
- Ferrous compounds have the limitation that they tend to oxidize rather readily, especially in alkaline environment, thus being converted to the less desirable ferric form. It is usual practice to attempt to counteract this tendency by adding reducing agents. However, many of the best reducing agents are toxic and those that are usable for pharmaceutical purposes may deteriorate rather rapidly during production and storage. The result is that by the time a preparation including such an agent reaches the patient a significant proportion of the ferrous compound may have been converted into the corresponding undesirable ferric form. Hence it is a principal purpose of the present invention to provide a preparation which contains the ferrous ion in readily absorbable form but which nevertheless is stable over a wide range of conditions and particularly those found in the gastrointestinal tract. 1,
- Another purpose ofthe present invention is to provide simple and efficient procedures for making such a preparation.
- ferrous complex which results from the reaction in an inert environment of ferrous sulphate and glycine.
- the resulting complex when administered orally, preferably in the form of a coated pill, has been found to be an excellent source of physiological iron. It is stable over the whole pH range found in the gastrointestinal tract, the same varying from weakly acid to alkaline. The complex is also quite stable in comparison with other ferrous compounds, there being no noticeable conversion to ferric forms. Clinical experience with the complex has demonstrated that iron therefrom is rapidly and etfectively absorbed.
- a preferred method of preparing the subject ironglycerine complex is as follows.
- the complex is preferably administered in the form of a coated pill, a sufiicient quantity of the same being incorporated in each pill so that the unit dose is equal to 40 mg. of ferrous ion.
- Work with the preparation has established that a good daily dosage is six tablets, i. e. a total of 240 mg.
- T able I Increase of iron concentration in Administered the serum in meg. dose of Fe" as a percent ferrous salt from t0 120 mg. 99 109 120 mg. 85 108 120 mg. 114 136 120 mg. Fe 68 240 mg. 25 126 240 mg. 42 65 240 mg. 102 126
- the starting iron concentration in blood serum in the case of most of the subjects described in Table I was extremely subnormal, nevertheless only a small portion of the iron administered was absorbed and incorporated in the serum. Contrast this with a set of observations made upon patients who received Ferrous Sulfate-Glycine Complex.
- Table II Increase of iron concentration in Administered the serum in mcg. dose of Fe as a percent glycine complex fromto- It is shown by Table II that despite the fact that the serum iron concentrations were substantially normal, 3.
- Ferrous Sulfate-Glycine Complex substantially free 10 of iron in therferric form.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DER17224A DE1042596B (de) | 1955-08-08 | 1955-08-08 | Verfahren zur Herstellung einer Eisen (ó�)-Glykokoll-Komplexverbindung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US2877253A true US2877253A (en) | 1959-03-10 |
Family
ID=7399926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US557838A Expired - Lifetime US2877253A (en) | 1955-08-08 | 1956-01-09 | Therapeutic iron complex |
Country Status (2)
| Country | Link |
|---|---|
| US (1) | US2877253A (de) |
| DE (1) | DE1042596B (de) |
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4183947A (en) * | 1977-01-13 | 1980-01-15 | Cockerill Vernon | Nutritional and therapeutic iron composition and method of making |
| EP0256645A2 (de) | 1986-07-03 | 1988-02-24 | Albion International, Inc. | Herstellung von reinen Aminosäurechelaten der pharmazeutischen Qualität |
| US6426424B1 (en) | 2000-10-11 | 2002-07-30 | Albion International, Inc. | Composition and method for preparing granular amino acid chelates and complexes |
| US6458981B1 (en) | 2000-10-11 | 2002-10-01 | Albion International, Inc. | Composition and method for preparing amino acid chelate hydroxides free of interfering ions |
| US6518240B1 (en) | 2000-10-11 | 2003-02-11 | Albion International, Inc. | Composition and method for preparing amino acid chelates and complexes |
| WO2003049850A2 (fr) * | 2001-12-11 | 2003-06-19 | Pancosma Societe Anonyme Pour L'industrie Des Produits Biochimiques | Oligo-element en poudre, procede et dispositif pour sa fabrication |
| US20030158171A1 (en) * | 2001-11-28 | 2003-08-21 | Albion International, Inc. | Chelates and complexes for reduction in alcohol dependency |
| FR2843752A1 (fr) * | 2002-08-26 | 2004-02-27 | Pancosma Sa Pour L Ind Des Pro | Oligo-elements cristallins, et procedes pour leur fabrication |
| US6710079B1 (en) | 2000-10-11 | 2004-03-23 | Albion International, Inc. | Composition and method for preparing amino acid chelates and complexes free of interfering complex ions |
| US20060013892A1 (en) * | 2001-11-28 | 2006-01-19 | Albion International Inc. | Administration of amino acid chelates for reduction in alcohol dependency |
| US20060276538A1 (en) * | 2001-11-28 | 2006-12-07 | Ashmead H D | Metal carnitine chelates |
| US20080194407A1 (en) * | 2007-02-14 | 2008-08-14 | Ashmead H Dewayne | High nitrogen containing chelate compositions suitable for plant delivery |
| WO2009089493A2 (en) * | 2008-01-11 | 2009-07-16 | Albion International, Inc. | Nitrate amino acid chelates |
| EP2719289A1 (de) | 2012-10-12 | 2014-04-16 | SC Medisan 2010 SRL | Verfahren zum Erhalt von Aminosäurechelaten mit Mikroelementen |
| WO2018192686A1 (de) | 2017-04-21 | 2018-10-25 | Technische Universität Clausthal | Energie-effizientes lösungsmittelfreies verfahren zur herstellung von metallchelaten |
| DE102018113243A1 (de) | 2018-06-04 | 2019-12-05 | BIOCHEM Zusatzstoffe Handels- und Produktionsgesellschaft mbH | Verfahren zur Herstellung einer Zusammensetzung enthaltend zumindest eine Metall-Aminosäure-Verbindung sowie Zusammensetzung erhältlich durch ein derartiges Verfahren |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2215233A (en) * | 1937-11-13 | 1940-09-17 | Simon L Ruskin | Iron compound of nucleotides and their organic hydrolytic decomposition products and method of making same |
| US2265271A (en) * | 1940-10-07 | 1941-12-09 | Desnoyers Sarto | Phosphogluconate of iron |
| US2683157A (en) * | 1952-10-02 | 1954-07-06 | Du Pont | Carboxycyclopentadienyl (cyclopentadienyl) iron |
| US2688032A (en) * | 1952-09-23 | 1954-08-31 | Sylvania Electric Prod | Preparation of ferrous formate |
| US2700048A (en) * | 1950-08-19 | 1955-01-18 | Bayer Ag | Process of producing organometallic compounds |
-
1955
- 1955-08-08 DE DER17224A patent/DE1042596B/de active Pending
-
1956
- 1956-01-09 US US557838A patent/US2877253A/en not_active Expired - Lifetime
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2215233A (en) * | 1937-11-13 | 1940-09-17 | Simon L Ruskin | Iron compound of nucleotides and their organic hydrolytic decomposition products and method of making same |
| US2265271A (en) * | 1940-10-07 | 1941-12-09 | Desnoyers Sarto | Phosphogluconate of iron |
| US2700048A (en) * | 1950-08-19 | 1955-01-18 | Bayer Ag | Process of producing organometallic compounds |
| US2688032A (en) * | 1952-09-23 | 1954-08-31 | Sylvania Electric Prod | Preparation of ferrous formate |
| US2683157A (en) * | 1952-10-02 | 1954-07-06 | Du Pont | Carboxycyclopentadienyl (cyclopentadienyl) iron |
Cited By (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4183947A (en) * | 1977-01-13 | 1980-01-15 | Cockerill Vernon | Nutritional and therapeutic iron composition and method of making |
| EP0256645A2 (de) | 1986-07-03 | 1988-02-24 | Albion International, Inc. | Herstellung von reinen Aminosäurechelaten der pharmazeutischen Qualität |
| US6710079B1 (en) | 2000-10-11 | 2004-03-23 | Albion International, Inc. | Composition and method for preparing amino acid chelates and complexes free of interfering complex ions |
| US6458981B1 (en) | 2000-10-11 | 2002-10-01 | Albion International, Inc. | Composition and method for preparing amino acid chelate hydroxides free of interfering ions |
| US6518240B1 (en) | 2000-10-11 | 2003-02-11 | Albion International, Inc. | Composition and method for preparing amino acid chelates and complexes |
| US6426424B1 (en) | 2000-10-11 | 2002-07-30 | Albion International, Inc. | Composition and method for preparing granular amino acid chelates and complexes |
| US20030158171A1 (en) * | 2001-11-28 | 2003-08-21 | Albion International, Inc. | Chelates and complexes for reduction in alcohol dependency |
| US20060013892A1 (en) * | 2001-11-28 | 2006-01-19 | Albion International Inc. | Administration of amino acid chelates for reduction in alcohol dependency |
| US20060276538A1 (en) * | 2001-11-28 | 2006-12-07 | Ashmead H D | Metal carnitine chelates |
| US7910137B2 (en) | 2001-11-28 | 2011-03-22 | Albion International, Inc. | Metal carnitine chelates |
| WO2003049850A2 (fr) * | 2001-12-11 | 2003-06-19 | Pancosma Societe Anonyme Pour L'industrie Des Produits Biochimiques | Oligo-element en poudre, procede et dispositif pour sa fabrication |
| WO2003049850A3 (fr) * | 2001-12-11 | 2003-10-23 | Pancosma Sa Pour L Ind Des Pro | Oligo-element en poudre, procede et dispositif pour sa fabrication |
| KR100952066B1 (ko) * | 2001-12-11 | 2010-04-13 | 빵코스마 소시에떼 아노님 뿌르 렝뒤스트리 데 프로뒤 비오시미끄 | 분말 미량 원소, 이의 제조방법 및 이의 제조장치 |
| FR2843752A1 (fr) * | 2002-08-26 | 2004-02-27 | Pancosma Sa Pour L Ind Des Pro | Oligo-elements cristallins, et procedes pour leur fabrication |
| US20080194407A1 (en) * | 2007-02-14 | 2008-08-14 | Ashmead H Dewayne | High nitrogen containing chelate compositions suitable for plant delivery |
| WO2009089493A3 (en) * | 2008-01-11 | 2010-01-14 | Albion International, Inc. | Nitrate amino acid chelates |
| US20090182044A1 (en) * | 2008-01-11 | 2009-07-16 | Ashmed H Dewayne | Nitrate amino acid chelates |
| WO2009089493A2 (en) * | 2008-01-11 | 2009-07-16 | Albion International, Inc. | Nitrate amino acid chelates |
| EP2719289A1 (de) | 2012-10-12 | 2014-04-16 | SC Medisan 2010 SRL | Verfahren zum Erhalt von Aminosäurechelaten mit Mikroelementen |
| WO2018192686A1 (de) | 2017-04-21 | 2018-10-25 | Technische Universität Clausthal | Energie-effizientes lösungsmittelfreies verfahren zur herstellung von metallchelaten |
| DE102017108611A1 (de) | 2017-04-21 | 2018-10-25 | Technische Universität Clausthal | Energie-effizientes lösungsmittelfreies Verfahren zur Herstellung von Aminosäure-Metallchelaten |
| US11649252B2 (en) | 2017-04-21 | 2023-05-16 | Technische Universitat Clausthal | Energy-efficient solvent-free method for producing metal chelates |
| DE102018113243A1 (de) | 2018-06-04 | 2019-12-05 | BIOCHEM Zusatzstoffe Handels- und Produktionsgesellschaft mbH | Verfahren zur Herstellung einer Zusammensetzung enthaltend zumindest eine Metall-Aminosäure-Verbindung sowie Zusammensetzung erhältlich durch ein derartiges Verfahren |
| WO2019233671A1 (de) | 2018-06-04 | 2019-12-12 | BIOCHEM Zusatzstoffe Handels- und Produktionsgesellschaft mbH | Verfahren zur herstellung einer zusammensetzung enthaltend zumindest eine metall-aminosäure-verbindung sowie zusammensetzung erhältlich durch ein derartiges verfahren |
Also Published As
| Publication number | Publication date |
|---|---|
| DE1042596B (de) | 1958-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US2877253A (en) | Therapeutic iron complex | |
| US20210299168A1 (en) | Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same | |
| US9757416B2 (en) | Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same | |
| Neuvonen | Interactions with the absorption of tetracyclines | |
| JP2023095949A (ja) | β酸化水酸化鉄を実質的に含まないクエン酸第二鉄 | |
| US2957806A (en) | Process for raising blood serum iron levels and controlling anemia | |
| KR840000229A (ko) | 디피리다몰의 경구용 제형의 제조방법 | |
| JPS59205322A (ja) | 骨からのカルシウムの過剰減少に伴なう疾病の治療用薬剤 | |
| EP1318804B1 (de) | Eisenverbindungen | |
| US5006551A (en) | Composition for destroying malignant tumors | |
| US3830824A (en) | Physiological organic acid silver allantoinates | |
| US3829561A (en) | Iron preparation and process for its manufacture | |
| Kandel et al. | Chronic arsenical poisoning during the treatment of chronic myeloid leukemia | |
| JPH0563452B2 (de) | ||
| EP0372676A1 (de) | Therapeutisches Präparat und Verfahren | |
| US3062719A (en) | Trisodium calcium diethylenetriaminepentaacetic acid, compositions containing the same, and the use thereof | |
| JP3348849B2 (ja) | ３−ヒドロキシ−４−ピロンのガリウム錯体の医薬組成物 | |
| US3062722A (en) | Therapeutic 2-aminoethanethiol orate | |
| Shepherd et al. | Chloramphenicol-induced aplastic anemia | |
| US2804423A (en) | Iron-vitamin composition | |
| AU629520B2 (en) | A medicament | |
| Mirabel et al. | (1) Penicillin Hypersensitivity Reaction with Purpura of Schönlein-Henoch Type, Acute Nephritis, and Angioneurotic (Œema.(2) Obesity and Diabetes Mellitus (Precipitated by Infection) | |
| US3322767A (en) | Tham salts | |
| US2098976A (en) | Medicinal preparations containing metal compounds of decomposition products of nucleoproteins | |
| Price et al. | UNCOATED BUFFERED FERROUS SULFATE: ABSORPTION IN MAN OF RADIOACTIVE IRON (FE 59) AS FERROUS SULFATE MEASURED ELECTRONICALLY |